IP Library Granted Patent US 9,566,243
Granted Patent B2
US 9,566,243 · App. 14/065,609 · Granted Feb 14, 2017

Apparatus and method for cryogranulating a pharmaceutical composition

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,566,243
App. No.
14/065,609
Granted
Feb 14, 2017
Kind
B2
Abstract

Cryogranulation systems with improved dispenser assemblies are provided for use in manufacturing frozen pellets of pharmaceutical substances in a fluid medium. Methods of cryogranulating the pharmaceutical substance in the fluid medium are also provided. In particular embodiments, the dispenser assembly is used with suspensions or slurries of pharmaceutical compositions including biodegradable substances, such as proteins, peptides, and nucleic acids. In certain embodiments, the pharmaceutical substance can be adsorbed to any pharmaceutically acceptable carrier particles suitable for making pharmaceutical powders. In one embodiment, the pharmaceutical carrier can be, for example, diketopiperazine-based microparticles. The dispenser assembly improves the physical characteristics of the cryopellets formed and minimizes product loss during processing.

Claims (15)

1. A composition comprising a plurality of substantially homogeneous frozen pellets of a pharmaceutical composition comprising diketopiperazine microparticles, wherein said composition is formed by dispensing a solution or a suspension of the pharmaceutical composition through a dispenser assembly into a flow of a cooling agent to form the frozen pellets, the dispenser assembly including first and second rows of dispenser ports, the rows of dispenser ports being disposed perpendicularly with respect to the flow of the cooling agent, separating the frozen pellets from the cooling agent by a transport assembly, and transporting the frozen pellets to a pellet receptacle.

2. The composition of claim 1 wherein the pharmaceutical composition further comprises a pharmaceutically active ingredient or agent.

3. The composition of claim 1 , wherein the substantially homogeneous frozen pellets range in diameter from 3-6 mm.

4. The composition of claim 1 , wherein the diketopiperazine has the formula:

5. The composition of claim 2 , wherein the pharmaceutically active agent comprises a peptide, protein or nucleic acid molecule.

6. The composition of claim 2 , wherein the active agent is insulin.

7. The composition of claim 2 , wherein the active agent is GLP-1.

8. The composition of claim 2 , wherein the active agent is oxyntomodulin.

9. The composition of claim 2 , wherein the active agent is parathyroid hormone or calcitonin.

10. The composition of claim 1 , wherein 41% or more of the pellets have diameters greater than 4.75 mm.

11. The composition of claim 1 , wherein 22% or less of the pellets have diameters less than 3.35 mm.

12. A composition comprising a plurality of homogenous frozen pellets comprising diketopiperazine microparticles, the frozen pellets being formed by dispensing a pharmaceutical suspension through a dispenser assembly into a flow of a cooling agent to form the frozen pellets, the dispenser assembly including first and second rows of dispenser ports, the rows of dispenser ports being disposed perpendicularly with respect to the flow of the cooling agent, wherein the dispenser ports of the first and second rows are angled with respect to vertical and wherein the dispenser ports of the first row are disposed at opposite angles with respect to the dispenser ports of the second row, separating the frozen pellets from the cooling agent, and transporting the frozen pellets to a pellet receptacle.

13. The composition of claim 12 , wherein the cooling agent is liquid nitrogen.

14. The composition of claim 12 , wherein the pharmaceutical suspension comprises diketopiperazine-based microparticles in a fluid medium.

15. The composition of claim 13 , wherein the pellets range in diameter from 3-6 mm.

Assignments (5)
PATENT SECURITY AGREEMENT Recorded Aug 12, 2025
From: MANNKIND CORPORATION
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 072444/0525 →
RELEASE OF SECURITY INTEREST Recorded Apr 5, 2024
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: MANNKIND CORPORATION; MANNKIND LLC
Reel/Frame 067024/0082 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2019
From: DEERFIELD PRIVATE DESIGN FUND II, L.P.; DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.; HORIZON SANTE FLML SARL
To: MANNKIND CORPORATION
Reel/Frame 050044/0138 →
SECURITY INTEREST Recorded Aug 13, 2019
From: MANNKIND CORPORATION; MANNKIND LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 050044/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2018
From: AMORO, EDWIN; VANACKERE, KAREL; WHITE, MICHAEL A.
To: MANNKIND CORPORATION
Reel/Frame 046500/0677 →